CVS Health has made a move on the US biosimilars category with the launch of Cordavis, a new business unit that will work with other drugmakers to bring private-label bios
AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a
First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f
This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the
Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.
Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho